Report from ICER and NEWDIGS suggests strategies, reforms to help payers adjust to one-time therapies
Market Access
Product Development
Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
Deals
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
Management Tracks
Plus: Novartis proposes Giovanni Caforio as chair and updates from Congruence, Recludix, Calluna and more
BioCentury ISSN 1097-7201